IL-17A Ab prevented ICH-induced cytokine expression and downstream signaling molecules.
IL-17A Ab attenuated microglial activation.
IL-17A Ab significantly reduced brain water content and improved neurological function of ICH mice.
IL-17A Ab might also provide a promising therapeutic strategy in ICH.